Day: November 10, 2025

GEORGE TOWN, Cayman Islands, Nov. 10, 2025 (GLOBE NEWSWIRE) — Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water supply and treatment plants, reported results for the third quarter ended September 30, 2025. All comparisons are to the same prior year period unless otherwise noted. Consolidated Water will hold a conference call at 11:00 a.m. Eastern time tomorrow to discuss the results (see dial-in information below). Third Quarter 2025 Financial SummaryTotal revenue increased 5% to $35.1 million. Retail revenue increased 2% to $7.8 million. Bulk revenue decreased 4% to $8.4 million. Services revenue increased by 13% to $14.3 million as construction revenue increased 50% to $6.4 million and operations and maintenance (O&M) revenue increased 3% to $7.7...

Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter Third Quarter 2025 Financial Highlights (all comparisons are to the prior year period)Worldwide revenue of $48.7 million, representing growth of 20.6%   U.S. revenue of $46.4 million, representing growth of 21.2% Gross margin of 79.8%, representing an improvement of 75 basis points Net loss of $4.6 million, representing an improvement of 30.6%   Positive adjusted EBITDA of $2.3 million Positive cash from operating activities of $2.3 million $145.7 million in cash and equivalentsRecent Operational Highlights (any comparisons are to the prior year period)1,530 active U.S. physicians, representing growth of 27%       $2.1 million in trailing 12-month average revenue per territory, representing an increase...

Q3 Annual Subscription Revenue Up 11.2% (Currency Neutral 9.3%), Representing 58.4% of Total Revenue Strong Q3 Profitability: 9.0% Net Income margin and 32.8% Adjusted EBITDA margin Updates 2025 Revenue and Adjusted EBITDA Guidance Finalizes Strategic Partnerships to Integrate Getty Images Content into Emerging AI PlatformsNEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — Getty Images Holdings, Inc. (“Getty Images” or the “Company”) (NYSE: GETY), a preeminent global visual content creator and marketplace, today reported financial results for the third quarter ended September 30, 2025. “Third quarter results were in line with our expectations, with top-line growth flattening due to challenging year-over-year comparisons against last year’s robust event calendar,” said Craig Peters, Chief Executive Officer at Getty Images. “We were pleased...

Signed Definitive Agreement to Acquire eSelf.aiRepurchased 14.4 million shares of common stock / $16.6 million of common stock from Goldman Sachs NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — Kaltura, Inc. (Nasdaq: KLTR, “Kaltura” or the “Company”), the Video Experience Cloud, today announced financial results for the third quarter ended September 30, 2025, as well as outlook for the fourth quarter and full year 2025. “We exceeded the upper end of all our third quarter guidance ranges, delivering record adjusted EBITDA profit, and strong operating cash flow,” said Ron Yekutiel, Co-founder, Chairman, President, and CEO of Kaltura. “We’ve entered the fourth quarter of the year with a strong pipeline and continue to project growth in new bookings in the coming quarter, supported by continued customer consolidation around our platform...

ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) —Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) following positive FDA meeting OCS-01 DIAMOND Phase 3 trials in diabetic macular edema (DME) remain on track for topline results expected in Q2 2026 Licaminlimab PREDICT-1 registrational trial, the first genotype-based trial to drive precision medicine in dry eye disease (DED), expected to start in Q4 2025 Cash, cash equivalents and short-term investments of $182.2 million as of September 30, 2025 plus recent $110 million financing, extend cash runway into 2029Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations...

Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) following positive FDA meeting OCS-01 DIAMOND Phase 3 trials in diabetic macular edema (DME) remain on track for topline results expected in Q2 2026 Licaminlimab PREDICT-1 registrational trial, the first genotype-based trial to drive precision medicine in dry eye disease (DED), expected to start in Q4 2025 Cash, cash equivalents and short-term investments of $182.2 million as of September 30, 2025 plus recent $110 million financing, extend cash runway into 2029ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations...

CHANDLER, Ariz., Nov. 10, 2025 (GLOBE NEWSWIRE) — VirTra, Inc. (Nasdaq: VTSI) (“VirTra” or the “Company”), a global provider of judgmental use-of-force and firearms training simulators, reported results for the third quarter ended September 30, 2025. The financial statements are available on VirTra’s website and here. Third Quarter 2025 and Recent Operational HighlightsBookings totaled $8.4 million in Q3 2025. Secured a $4.8 million multi-site contract to deliver law enforcement training systems in Colombia. Validated and approved for full deployment of 20 simulators with the Royal Canadian Mounted Police, expanding VirTra’s installed base and training footprint across Canada. Introduced the V-One Portable Simulator, a compact, high-quality training solution tailored for smaller agencies and mobile training environments. Demonstrated...

– Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital herpes – – Announced Phase 1a interim results for orally bioavailable HDV entry inhibitor candidate ABI-6250 supporting progression into Phase 2 evaluation – – Additional interim Phase 1b data readouts from HSV program anticipated to include monthly oral dosing for ABI-5366 and two cohorts of weekly oral dosing for ABI-1179, with data now expected by end of year – – Raised $175 million gross proceeds from equity financings – SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today...

– Q3 Total Revenue up 40% YoY to $146.8 Million –– Q3 Net Income Increases to $23.9 Million or $0.56 Earnings per Share –– Q3 Operating Cash Flow of $23.2 Million –– Q3 Adjusted EBITDA up 1.6x to $24.9 Million –– Filed ERAS Application for 525MW Gas Generation Expansion – TERRE HAUTE, Ind., Nov. 10, 2025 (GLOBE NEWSWIRE) — Hallador Energy Company (Nasdaq: HNRG) (“Hallador” or the “Company”) today reported its financial results for the third quarter ended September 30, 2025.  “This was an exceptional quarter for Hallador as we delivered significant gains across all key financial metrics, including material growth in revenue, net income, Adjusted EBITDA and cash flow from operations,” said Brent Bilsland, President and Chief Executive Officer. “Favorable summer weather,...